3 results
Our study tries to identify the ideal sclerosant dosage for the ClariVein® system in order to occlude the GSV permanently. By choosing the lowest dose with the same anatomical success rate, we achieve a safe treatment which also gives us the…
CAEB071A2206 will assess safety, efficacy and target trough levels for optimal dosing of AEB071 combined with Certican in a CNI-free regimen in de novo renal transplant recipients. This study will combine the investigational drug AEB071 with an…
Primary Efficacy Objective:Primary objective: To evaluate if the addition of ISA101b to cemiplimab results in improved overall response rate (ORR) compared to cemiplimab alone, according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1…